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A B S T R A C T
Introduction: To advance the use of alcohol metabolites as biomarkers in the context of alcohol research, the
present study tested the sensitivity and specificity of a commercially available urinary ethyl glucuronide (uEtG)
test (DrugConfirm Advanced 80hr EtG) in a clinical research context.
Methods: A community sample of heavy drinkers (N = 68) completed the 30-day Timeline Follow-Back (TLFB)
interview and provided a urine sample for uEtG analysis. Analyses of sensitivity and specificity of the uEtG assay
were conducted using the following outcomes: (a) past day drinking, (b) past day binge drinking (defined as≥4
drinks for women and ≥5 drinks for men), (c) past 3-day drinking, and (d) past 3-day binge drinking.
Results: The majority of participants reported past-3-day drinking (80.9%) and a sizeable minority reported past
day drinking (33.8%). While uEtG-based detection of past day drinking and binge drinking was acceptable
(sensitivity = 73.91%, and 83.33%; specificity = 80.00% and 66.13%, respectively), detection of any drinking
and binge drinking in the past 3 days was poor (sensitivity and specificity of 43.64% and 84.62%, and 39.39%
and 62.86%, respectively).
Conclusions: This study contributes to the mixed findings on the validity of EtG tests, which suggest that com-
mercial uEtG tests with conservative detection thresholds are not a reliable alcohol biomarker without corro-
borating self-report data. Lower detection thresholds are recommended when using uEtG as an alcohol bio-
marker. Efforts to reach acceptable levels of sensitivity and specificity with commercial assays hold potential to
advance the measurement of alcohol intake, overcoming the pitfalls of self-report data.
1. Introduction
Research with alcohol using populations commonly relies on stan-
dardized self-report measures to assess an individual’s alcohol intake.
Recently, interest in biochemical markers of alcohol use has increased,
as biomarkers offer advantages over self-report measures to indicate
alcohol use independent of recall bias or other motivating factors.
However, alcohol biomarkers can be less sensitive than well-standar-
dized self-report measures, and to date, no biomarker has gained
widespread acceptance as a primary outcome measure of alcohol use
(Kalapatapu & Chambers, 2009; Litten, Bradley, & Moss, 2010; Roberts
& McKee, 2018; Shorter et al., 2019). The potential utility of bio-
markers for alcohol research are multiple and include serving as an
objective outcome measure in treatment settings and research studies,
screening for alcohol use in individuals who are unable to provide valid
self-report data, and establishing abstinence among individuals
mandated to abstain from drinking (Jastrzebska et al., 2016). However,
in order for the promise of alcohol use biomarkers to be realized,
practical assays (i.e. those which can be conducted solely within a
treatment and/or research setting) with strong sensitivity, specificity,
and a clear understanding of their window of detection are needed.
The field of alcohol biomarkers has traditionally relied on indirect
markers, such as gamma-glutamyl-transpeptidase (GGT), aspartate
aminotransferase (AST) and alanine aminotransferase (ALT), mean
corpuscular volume (MCV), and carbohydrate deficient transferrin
(CDT). However, these markers are influenced by a host of inter-
individual differences, non-alcohol related illnesses, and tend to cap-
ture only long term alcohol use (Wurst et al., 2015). More recently,
direct ethanol metabolites have received increased attention as they
represent minor pathways of ethanol elimination with the potential for
higher sensitivity and specificity than indirect makers. The most fre-
quently used measures include ethyl glucuronide (EtG), ethyl sulphate
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(EtS), and phosphatidylethanol (PEth).
EtG is a phase 2 metabolite of alcohol that can be detected in urine,
whole blood, serum, and hair (Foti & Fisher, 2005; Kissack, Bishop, &
Roper, 2008; Wurst et al., 2015). EtG can be detected in urine for up to
80 h after ethanol consumption depending on the amount of alcohol
consumed (Kissack et al., 2008; Wurst et al., 2015). Few studies have
assessed the ability of commercially available urinary EtG tests detect
recent alcohol use. One study used a commercial test to detect alcohol
use among non-drinking, former drinking, and current drinking HIV-
Hepatitis B virus co-infected individuals in Zambia (Vinikoor et al.,
2018), while another study used a commercial test to detect light
drinking among women of childbearing age (Graham, Beatty, Rosano,
Sokol, & Ondersma, 2017). Whereas the first study found support for
the use of a point-of-care urinary EtG test using a 500 ng/dl detection
cutoff (Vinikoor et al., 2018), the second study, which consisted of a
controlled alcohol administration and 3-day follow-up period, found
that an uEtG cutoff of> 100 ng/dl (representative of those used by
commercial laboratories) was not sensitive enough to reliably detect
light-to-moderate drinking beyond a 12-hour window (Graham et al.,
2017). Studies that have assessed urinary EtG using more sensitive la-
boratory measures such as liquid chromatography-mass spectrometry
(LC-MS) in alcohol using populations have found that uEtG has good
sensitivity and specificity for the detection of recent drinking (Armer,
Gunawardana, & Allcock, 2017; Dahl, Voltaire Carlsson, Hillgren, &
Helander, 2011; Stewart, Koch, Burgess, Willner, & Reuben, 2013;
Wurst, Wiesbeck, Metzger, & Weinmann, 2004). However, uEtG using
these advanced laboratory techniques may be too sensitive in that it
also captures incidental exposure to other alcohol sources (e.g., hand
sanitizer, mouthwash), resulting in false positives (Costantino,
DiGregorio, Korn, Spayd, & Rieders, 2006). Additionally, if a urine
sample is stored in room temperature for more than 12 h, yeast may
convert urine glucose into ethanol, and therefore, EtG (Kissack et al.,
2008). Enzyme immunoassays have been developed as an alternative to
the costly and potentially overly-sensitive LC-MS method (Böttcher,
Beck, & Helander, 2007). This method has high sensitivity and good
agreement with LC-MS results. However, the enzyme immunoassay
method still requires advanced laboratory instruments which may not
be ideal in clinical research contexts.
In sum, there is a strong need for research regarding biomarker
assay cutoff values and associated detection windows in research con-
texts (SAMHSA, 2006, 2012). To advance the use of alcohol metabolites
as biomarkers in the context of alcohol research, the present study
tested the sensitivity and specificity of a commercially available urine
EtG test to detect recent alcohol drinking in a clinical research sample
of heavy drinkers.
2. Methods
2.1. Participants
The study protocol and all procedures were approved by the
Institutional Review Board of the University of California, Los Angeles.
Participants were recruited from the greater Los Angeles community
through fliers, online and print advertisements, and social media. Study
advertisements targeted individuals who drank alcohol, but did not
specify specific study inclusion or exclusion criteria. Inclusion criteria
were as follows: (1) heavy drinking, indicated by a score of 8 or higher
on the Alcohol-Use Disorders Identification Test (AUDIT) (Saunders,
Aasland, Babor, De la Fuente, & Grant, 1993), signifying a hazardous
drinking pattern, or drinking 14+ drinks per week for men or 7+
drinking per week for women and as defined by the National Institute
on Alcohol Abuse and Alcoholism (NIAAA); and (2) between the ages of
21 and 65. Participants (N = 68) for this study were selected as a
convenience sample from three completed or ongoing behavioral
pharmacology studies of heavy drinkers that collected both uEtG and
Timeline Follow-back (TLFB) (Sobell, Sobell, Klajner, Pavan, & Basian,
1986). Study 1 (N = 17) examined the relationship between subjective
response and self-administration of alcohol (Bujarski et al., 2018).
Study 2 (N = 46) is ongoing and tests the combination of varenicline
and naltrexone for smoking cessation among heavy drinking smokers.
Study 3 (N = 6) compared treatment-seekers versus non-treatment
seekers for alcohol use disorders (AUD) on alcohol cue-reactivity in the
laboratory (Venegas & Ray, 2019). Since there was no imposed or im-
plied upper limit on drinking, participants were not motivated to un-
derreport or otherwise misrepresent their alcohol use. Additionally, this
data was collected during a behavioral screening visit, and therefore,
participants were not informed of necessary inclusion/exclusion criteria
regarding their drinking, nor were they influenced by clinician in-
volvement to underreport their alcohol use. Participants were com-
pensated $30 for completing the behavioral screening visit.
2.2. Procedures
Initial assessment of the eligibility criteria was conducted through a
telephone interview. Eligible participants were invited to the laboratory
for an in-person assessment. All participants read and signed an in-
formed consent form upon receiving a full explanation of all study
procedures. Participants then provided a urine sample for EtG analysis
and completed individual differences questionnaires and interviews. All
participants were required to test negative for drugs of abuse on a urine
drug test (except for marijuana) and to have a BrAC of 0.00 g/dl at the
assessment visit. All female participants tested negative for pregnancy.
2.3. Measures
The Timeline Follow-back (TLFB) (Sobell et al., 1986) was used to
assess for quantity and frequency of drinking over the past 30 days. The
DrugConfirm Advanced 80hr EtG urine drug test, obtained from Con-
firm Biosciences, was used as a point-of-care test that is commercially
available. Urine samples were collected at the beginning of study visit
and the uEtG test was analyzed within 5 min of collection. This dipped
urine EtG test strip had a detection threshold of 500 ng/ml and pro-
vided a qualitative (positive/negative) result, indicated by the number
of lines on the test strip (1 = positive, 2 = negative). A threshold of
500 ng/ml is interpreted as indicating previous heavy drinking
(1–3 days), light drinking (12–36 h), and excludes most cases of in-
cidental exposure to alcohol (Jatlow et al., 2014; SAMHSA, 2006,
2012). The study team did not disclose the results of uEtG tests to
participants, thus reducing possible reporting bias during the TLFB in-
terview.
Measures of alcohol use and alcohol use disorder severity were also
collected. The Structured Clinical Interview for DSM-5 (SCID; adapted
from (First, Williams, Karg, & RL, 2015)) assessed for lifetime and
current AUD. Participants also completed the Alcohol Use Disorders
Identification Test (AUDIT (Allen, Litten, Fertig, & Babor, 1997)) and
the Penn Alcohol Craving Scale (PACS (Flannery, Volpicelli, & Pettinati,
1999)). Of note, 6 participants in this sample did not complete the
AUDIT.
2.4. Data analysis
All analyses were conducted in R version 3.3. Self-reported recent
alcohol consumption from the TLFB interview was used as the reference
test. Participants were coded based on the four primary variables of
interest: past day drinking, past day binge drinking, past 3-day
drinking, and past 3-day binge drinking, all taken from the TLFB in-
terview. Binge drinking was defined as ≥4 drinks for women and ≥5
drinks for men by NIAAA (https://www.niaaa.nih.gov/alcohol-facts-
and-statistics). Sensitivity and specificity were computed from fre-
quency tables with sensitivity defined as the number of true detected
positives/total positives and specificity defined as the number of true
detected negatives/total negatives. McNemar's χ2 tests were also
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conducted to determine whether the accuracy of the EtG test reached
statistical significance.
3. Results
3.1. Sample characteristics
Of the 68 participants enrolled in this study, 40% (N = 27) were
female. The average age was 36.49 (SD = 12.62), On average, parti-
cipants reported drinking on 16.79 of the past 30 days (SD = 9.00),
binge drinking on 8.35 days (SD = 8.88) of the past 30 days, and
consuming 5.34 drinks per drinking day (SD = 3.55). See Table 1 for a
full description of participant characteristics.
3.2. Sensitivity and specificity of urinary EtG
Analyses of sensitivity and specificity were conducted using the
following endpoints derived from the TLFB interview: (a) past day
drinking, (b) past day binge drinking (defined as≥4 drinks for women
and ≥5 drinks for men), (c) past 3-day drinking, and (d) past 3-day
binge drinking. 33.8% (N = 23) of participants reported past day
drinking (average number of drinks consumed in the past day = 1.26
(SD = 2.50)), while 80.9% (N = 55) reported past 3-day drinking
(average number of drinks consumed over the past 3 days = 8.43
(SD = 10.57)). Past day binge drinking was reported by 8.8% (N = 6)
of participants, while 3-day binge drinking was reported by 48.5%
(N = 33) of participants. As shown in Table 2, sensitivity and specifi-
city for the urine EtG test were acceptable for detecting past day
drinking (sensitivity = 73.91%, specificity = 80.00%, χ2 (1) = 18.73,
p < 0.001). Specifically, 9 participants reported no past-day drinking
during the TLFB interview but had a positive uEtG result. Similarly,
sensitivity and specificity for the uEtG test were acceptable for de-
tecting past day binge drinking (sensitivity = 83.33%, sensitivity
66.13%, χ2 (1) = 5.67, p < 0.001); one participant reported past day
binge drinking during the TLFB interview but did not have a positive
uEtG result. However, when examining the sensitivity and specificity of
the uEtG test in detecting drinking within a 3-day window, performance
was well below standard thresholds (past 3-day drinking: sensi-
tivity = 43.64%, specificity = 84.62%, χ2 (1) = 2.94, p = 0.11; past
3-day binge drinking: sensitivity = 39.39%, specificity = 62.86%, χ2
(1) = 0.04, p = 0.30). These results suggest that when using this
commercially available uEtG test with a detection cutoff of 500 ng/mL,
detection of past 3-day drinking, or even past 3-day binge drinking did
not exceed chance.
4. Discussion
The present study sought to test the validity of a commercially
available uEtG test to detect past day drinking, past day binge drinking,
past 3-day drinking, and past 3-day binge drinking in a sample of heavy
drinkers. We found that while uEtG was reasonably able to detect past
day alcohol use and past day binge drinking, detection of drinking and
binge drinking in the past 3 days was poor. These findings were con-
sistent with a recent study examining the utility of uEtG testing among
women of childbearing age, which found poor sensitivity to detect
light-to-moderate drinking beyond a 12-hour window (Graham et al.,
2017). These preliminary results call into question the validity of
commercially available urine EtG tests at the manufacturer re-
commended detection cutoffs as means of validating alcohol abstinence
and binge drinking in clinical research. It is important to consider the
sensitivity of detection window as the current uEtG was commercially
sold to detect alcohol use in the past 80 h, yet was only accurate for
detecting past 24 h’ alcohol use. As false positives are common with
uEtG tests (Costantino et al., 2006; Wurst et al., 2015), researchers
should be aware of the limitations of urinary EtG using the manu-
facturer recommended detection threshold of 500 ng/ml and should not
rely on commercial uEtG alone as verification of past alcohol use,
particularly when using conservative detection thresholds. Breath al-
cohol concentrations (BrAC) should be used in conjunction with phy-
siological biomarkers and self-report in order to accurately capture
recent alcohol intake.
Several limitations from the present study must be considered. The
urine EtG test used in the current study had a threshold of 500 ng/ml,
which is a conservative detection threshold based on prior studies
(Jatlow et al., 2014; SAMHSA, 2006; Vinikoor et al., 2018) and may be
more appropriate for use in forensic settings where non-beverage al-
cohol use is more common. This suggests that the uEtG test could be
more sensitive if a lower detection threshold was implemented. Sec-
ondly, this study only used a self-report measure of drinking (TLFB) to
validate uEtG as a biomarker. Because the TLFB interview only collects
information on a drinking by day basis, we could not assess the number
of hours since the last drink and thus used number of days since last
drink as our reference measure. Future studies should compare the
commercial test with other measures of alcohol consumption, such as
LC-MS/MS methods, wearable biochemical sensors (Panneer Selvam,
Muthukumar, Kamakoti, & Prasad, 2016), or ecological momentary
assessment self-reports. Third, this study had a small sample size col-
lected from a convenience sample. Future studies should enroll larger
samples to examine the sensitivity of point-of-care tests.
Identifying reliable and sensitive alcohol biomarkers represents an
Table 1
Participant characteristics.
Mean + SD Range
Age 36.49 ± 12.62 21–62
Sex (M/F) 41/27 –
Ethnicity
Caucasian (%)
African American (%)
Latino (%)
Asian (%)
Other/Unknown (%)
31
(45.6%)20
(29.4%)15
(22.1%)1
(1.5%)1
(1.5%)
–
Total Drinks (30 Days) 97.00 ± 83.73 1.68–375.84
Number of Drinking Days (30 Days) 16.79 ± 9.00 1–30
Drinks Per Drinking Day (30 Days) 5.34 ± 3.55 0.84–21.27
Number of Binge Drinking Days (30 Days) 8.35 ± 8.88 0–30
AUD Diagnosis
None (%)
Mild (%)
Moderate (%)
Severe (%)
17
(25%)21
(30.9%)19
(27.9%)11
(16.2%)
–
AUDITa 15.03 ± 7.71 1–35
PACS 12.06 ± 6.29 0–29
a = data is missing from 6 participants.
Table 2
Sensitivity, specificity, and χ2 tests of the uEtG tests with respect to past day drinking, past 3-day drinking and past 3-day binge drinking.
Sensitivity (% of drinking detected) Specificity (% of non-drinking detected) χ2 df p
Past Day Drinking 73.91% 80.00% 18.73 1 <0.001
Past 3-Day Drinking 43.64% 84.62% 2.94 1 0.11
Past Day Binge Drinking 83.33% 66.13% 5.67 1 <0.001
Past 3-Day Binge Drinking 39.39% 62.86% 0.04 1 0.30
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important task to advance the field of alcoholism research and practice.
Provided they are accurate, alcohol biomarkers can serve as important
treatment outcomes in clinical trials and health care settings to detect,
monitor, and prevent alcohol use. The present study is the first in-
vestigation of the reliability of uEtG to detect recent drinking in a
clinical research sample of heavy drinking individuals using a com-
mercially available point-of-care test. Our findings contribute to the
mixed literature of the validity of EtG tests, which collectively suggest
uEtG measured with commercially available assays at conservative
cutoff thresholds (e.g. 500 ng/mL) are not reliable enough to serve as a
primary alcohol biomarker. Urine EtG tests using lower cutoffs
(100–200 ng/ML) appear to serve as more reliable predictors of heavy
alcohol use (Jatlow et al., 2014; McDonell et al., 2015), and as such,
these thresholds should be used in clinical research settings seeking to
use biological verification of heavy alcohol use. Continuous efforts to
reach acceptable levels of sensitivity and specificity with commercial
assays that are affordable, easily administered, and user-friendly hold
potential to advance the measurement of alcohol intake, ultimately
overcoming the pitfalls of self-report data.
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